Biopharmaceuticals
-
China's A-share market saw its three major indices rise collectively in early trading, with the ChiNext Index once gaining over 1%. Hong Kong's Hang Seng Tech Index surged before pulling back to losses, while the Biotech Index soared nearly 5%. Crude oil prices fell sharply by 6%.
On September 21st, A-shares collectively rose in early trading, with the Shanghai Composite Index up 0.50%, the Shenzhen Component Index up 0.80%, and the ChiNext Index up 1.29%. The biomedical sector
-
China has released a new five-year plan for biomedicine, aiming to capture 25% of the global market for first-in-class drugs by 2030.
Chinese authorities stated on Friday that, under a new five-year plan, China aims to become a global biopharmaceutical powerhouse by 2030, with goals to achieve breakthroughs in key technologies and c
-
China's A-share market saw the Shanghai Composite Index fall by 0.38% in early trading, with the biomedical sector surging. CRO and innovative drug stocks rose sharply. Hong Kong stocks, including the Hang Seng Index and Hang Seng Tech Index, both fell by over 1%, with major tech stocks generally declining.
On the morning of September 17, A-share major indices opened lower and then fluctuated downwards. The Shanghai Composite Index fell by 0.38%, the Shenzhen Component Index remained flat, and the ChiNex
-
Hong Kong to unveil first five-year plan next week, targeting biomedicine powerhouse status; GSK expresses interest in region's biotech development on Wednesday
Hong Kong's inaugural five-year plan, set to be unveiled next week, will focus on establishing the city as a biomedicine powerhouse, signaling closer medical cooperation across the Greater Bay Area. G
-
WuXi AppTec's stock price surged 100% to an all-time high, as investors bet on its continued core position in the global drug supply chain.
WuXi AppTec's stock price hit a record high last week, doubling its January level, despite the U.S. Pentagon listing it as a Chinese military company, which could lead some American clients to withdra
-
China's A-share market saw its three major indices rise collectively in early trading, with the ChiNext Index once gaining over 1%. Hong Kong's Hang Seng Tech Index surged before pulling back to losses, while the Biotech Index soared nearly 5%. Crude oil prices fell sharply by 6%.
On September 21st, A-shares collectively rose in early trading, with the Shanghai Composite Index up 0.50%, the Shenzhen Component Index up 0.80%, and the ChiNext Index up 1.29%. The biomedical sector
-
China has released a new five-year plan for biomedicine, aiming to capture 25% of the global market for first-in-class drugs by 2030.
Chinese authorities stated on Friday that, under a new five-year plan, China aims to become a global biopharmaceutical powerhouse by 2030, with goals to achieve breakthroughs in key technologies and c
-
China's A-share market saw the Shanghai Composite Index fall by 0.38% in early trading, with the biomedical sector surging. CRO and innovative drug stocks rose sharply. Hong Kong stocks, including the Hang Seng Index and Hang Seng Tech Index, both fell by over 1%, with major tech stocks generally declining.
On the morning of September 17, A-share major indices opened lower and then fluctuated downwards. The Shanghai Composite Index fell by 0.38%, the Shenzhen Component Index remained flat, and the ChiNex
-
Hong Kong to unveil first five-year plan next week, targeting biomedicine powerhouse status; GSK expresses interest in region's biotech development on Wednesday
Hong Kong's inaugural five-year plan, set to be unveiled next week, will focus on establishing the city as a biomedicine powerhouse, signaling closer medical cooperation across the Greater Bay Area. G
-
WuXi AppTec's stock price surged 100% to an all-time high, as investors bet on its continued core position in the global drug supply chain.
WuXi AppTec's stock price hit a record high last week, doubling its January level, despite the U.S. Pentagon listing it as a Chinese military company, which could lead some American clients to withdra
- No data
Biopharmaceuticals
24H Trending
-
1
The Nikkei 225 index fell 2% from its previous close, currently trading at 59,918.04.
-
2
What was the initial offering price of DODO? Introduction to the DODO token issuance price
-
3
How to buy and sell REV3L token? Which exchanges is REV3L listed on?
-
4
Yemeni government forces say 173 Houthi fighters were killed or wounded in clashes across multiple fronts
-
5
From Coinbase Perpetual Contract Account Setup to Anti-Liquidation: A Practical Masterclass After the CFTC's Historic Approval 2026
-
6
Central Bank of Brazil Official's Remarks on Stablecoin Money Laundering Risks Spark Strong Market Backlash
-
7
CNN: U.S. intelligence warns Iran may plot dirty bomb or chemical attack in Washington
-
8
Bitcoin slips below $65,000, weighed down by U.S. stock declines driven by AI sentiment and NVIDIA earnings expectations
-
9
NVIDIA: Lambda deploys co-packaged optics switches in 10,000+ GPU cluster
-
10
SK Hynix is down 8.22% from its previous close, currently trading at ₩1,116,000.
Markets Today
Recommended Reading



